GlassScriptPhysician profile
Ashley Goodnight Hall
NPI 1790957587
$39,919.45
in general payments reported to CMS, 2019-2025
31 companies · $6,780 in 2025
The $6,780 reported for 2025 was more than what 86% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $874 · 2021: $1,272 · 2022: $2,000 · 2023: $2,643 · 2024: $25K · 2025: $6,780.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $6,809 · Travel and Lodging: $1,043 · Honoraria: $175 · Education: $49.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,750.00 |
| Food and Beverage | $6,808.84 |
| Travel and Lodging | $1,043.38 |
| Honoraria | $175.00 |
| Education | $49.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $31,570.32 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $1,070.98 | 2020-2025 | Takhzyro, Cuvitru, Eohilia |
| Regeneron Healthcare Solutions, INC. | $1,069.33 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $1,000.91 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $933.01 | 2019-2025 | |
| Genentech USA, INC. | $769.67 | 2019-2025 | Xolair |
| Pharming Healthcare, INC. | $543.06 | 2022-2025 | Ruconest, Joenja |
| Pfizer INC. | $406.73 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $358.82 | 2022-2025 | Orladeyo |
| Grifols USA, LLC | $351.63 | 2020-2024 | Xembify |
| Novartis Pharmaceuticals Corporation | $310.31 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $175.00 | 2024 | |
| Amgen INC. | $165.18 | 2022-2025 | Tezspire |
| Adma Biomanufacturing LLC | $160.13 | 2022 | |
| Galderma Laboratories, L.P. | $138.35 | 2025 | Nemluvio |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $115.02 | 2025 | Neffy |
| Shire North American Group INC | $96.89 | 2019 | |
| Csl Behring | $88.65 | 2022-2025 | Hizentra, Andembry |
| Ionis Pharmaceuticals, INC. | $86.31 | 2025 | Dawnzera, Donidalorsen |
| Teva Pharmaceuticals USA, INC. | $73.59 | 2019-2021 | |
| Incyte Corporation | $69.96 | 2021-2024 | Opzelura |
| Sanofi-Aventis U.S. LLC | $65.37 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.40 | 2021 | |
| Blueprint Medicines Corporation | $45.45 | 2024-2025 | Ayvakit |
| Optinose US, INC. | $38.38 | 2024 | |
| Alk-Abello, INC | $33.12 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $30.93 | 2021-2023 | |
| Greer Laboratories, INC. | $27.73 | 2025 | Palforzia |
| Abbvie INC. | $23.35 | 2022 | |
| Octapharma USA, INC. | $19.44 | 2025 | Cutaquig |
| Organon LLC | $17.43 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.